The number of patients with arrhythmia in China exceeds10 million. With China entering an aging society, the incidence of arrhythmia is increasing rapidly. Arrhythmia brings multiple physiological and economic pressures to patients and their families. At the same time, the growing patient population also brings great challenges to the national medical and health system. Pacemaker can help patients to improve heart function, make the heart pump blood regularly, and ensure the blood demand of patients' main organs.
Professor introduction:? Implantation of pacemaker is the only effective method to treat irreversible bradycardia. Today, the world's smallest leadless pacemaker has finally been put into clinical application at China International Import Expo (CIIE), realizing the synchronous development of medical technology and international counterparts. Compared with when cardiac pacing therapy was just introduced 30 years ago, the number of arrhythmia patients who benefited from cardiac pacing therapy in China increased by more than 30 times every year. The frontier innovation breakthrough of pacing therapy has met the people's growing demand for heart health medical services. ?
Professor cutie emphasized: Micra empowers medical science and technology with the people-oriented scientific and technological concept, innovates surgical methods, improves the prognosis of patients, reduces the overall treatment cost, and makes greater efforts to achieve an organic balance between accessibility and affordability of treatment, thus opening a new era of leadless pacing for arrhythmia treatment in China.
So how to improve the benefits of patients? The last mile of medical insurance? This is the next challenge that all parties will face. Improving the medical security level of cardiac pacing therapy for urban and rural residents can not only promote the popularization of innovative technology, but also provide higher quality health security for the majority of arrhythmia patients.